One Pipeline. Four CROs. Built for VHH Discovery
The Isogenica Discovery Network integrates specialist CROs into a seamless VHH ecosystem, from antigen prep to IND, delivering aligned handovers, faster timelines, and reduced risk.
The Discovery Network in Action
Four critical stages. One aligned workflow. Zero friction.
Why It Works
- Integrated platforms, assays, and data from day one
- Fewer contracts, faster setup, no workflow gaps
- Shared context → better decisions, earlier
- Strategic alignment from hit to IND
Built for Complex Targets
- Stabilized GPCRs and membrane proteins
- Intracellular, pH-sensitive, or isoform-specific targets
- Functional and internalization-dependent endpoints
- Species-selective and toxic-payload campaigns
Built for Next-Gen Modalities
- Conjugation-ready VHHs for ADCs and viral vectors
- Dual-target and internalizing formats
- Payload-compatible binders
Built for Biotech
- First-time VHH developers
- Switching from immunization-based methods
- Working with unstable or novel targets
- Planning for manufacturing early
From Hits to IND, Without the Handover Headache
Charles River provides a direct path to IND studies, combining scientific depth, regulatory insight, and global infrastructure. No duplication. No delays. One partner planning for clinical success from day one.
Capabilities That De-Risk Your Path to Clinic:
- GLP Preclinical Studies:Toxicology, pharmacology, immunogenicity, and developability tailored to VHHs, meeting global safety and regulatory standards.
- Manufacturing & Scale-Up: Research to GMP production, ensuring supply without provider changes
- Regulatory Strategy: IND planning, risk mitigation, and study design aligned with regulatory expectations.
- Seamless Workflow Integration: Compatible with Isogenica discovery and Axxam validation, preserving continuity.
- Modality-Ready Expertise: Proven in bispecifics, ADCs, and viral vectors for complex format advancement.
Rapid Functional Insight. Confident Lead Selection.
With Axxam’s expertise in high-throughput functional screening and mechanism-aware assay development, we triage VHHs not just for binding and developability, but for potency, specificity, internalisation, and biological relevance. The result: earlier clarity, confident lead selection, and reduced downstream risk.
Capabilities That Drive Better Decisions:
- High-Throughput Screening: Screen 1,000+ VHHs in custom assays to rapidly filter non-functional binders.
- Custom Assay Development: Tailored for uptake, trafficking, receptor signalling, agonism, and intracellular activity.
- Lead PrioritisationPrioritization & Ranking: Data interpreted with biological context to focus on the most potent, specific, and developable VHHs.
- Seamless Integration: Assay-ready formats from Isogenica minimise handovers and preserve continuit
- Modality-Ready Design: Assays validated for ADCs, bispecifics, intracellular and complex targets, aligned with downstream strategy.
The Right Antigen. In the Right Format. From Day One.
For GPCRs, ion channels, intracellular or conformationally sensitive targets, even the best discovery platform can’t overcome a poor-quality antigen. That’s why we partner with Cube Biotech, specialists in membrane protein stabilization. Their proprietary nanodisc technology delivers biologically relevant, high-integrity antigens optimised for synthetic VHH discovery. Start with confidence, stay on track.
Capabilities That Enable Better Discovery:
- Native-Conformation Membrane Proteins: Stabilised in lipid nanodiscs with proprietary polymers to preserve structure for high-quality binder selection.
- Synthetic Workflow Compatibility: Formats tailored for phage and CIS Display, maintaining integrity and reducing false positives
- State-Specific Antigens: Active, inactive, or internalised forms enable selection of state- or epitope-specific VHHs..
- Strategic Antigen Planning: Co-designed formats and expression strategies accelerate launch, minimise waste, and improve outcomes..
- Expertise in Complex Targets: Toxic, pH-sensitive, and multi-pass proteins de-risk challenging campaigns and reduce animal use.
Partnerships at Isogenica
Despite the confidentiality of our clients, Isogenica consistently receives high satisfaction ratings, with 100% of VHH discovery customers rating between 8 and 10/10 on how likely they would be to recommend our organization to a friend or colleague. Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including three clinical-stage assets (Phase I and Phase II) and dozens of partnered pre-clinical and discovery programs. Contact us to find out how to revolutionise your research and development with VHH antibody technologies.